Avient has transitioned our Material Safety Data Sheets (MSDSs) to Safety Data Sheets (SDSs) for our manufactured products to meet the requirements of the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), and CLP classification in Europe. Technical Data Sheets Safety Data Sheets

intends to use the net proceeds from the offering to finance, in part, its pending acquisitions of Clariant AG's global masterbatch business (the "Clariant masterbatch acquisition") and Clariant Chemicals (India) Limited's masterbatch business (collectively, the "acquisitions"). The notes will be subject to a "special mandatory redemption" in the event that (i) the Clariant masterbatch acquisition is not consummated on or prior to the purchase agreement is terminated, other than in connection with the consummation of the Clariant masterbatch acquisition.

intends to use the net proceeds from the offering to finance, in part, its pending acquisitions of Clariant AG's global masterbatch business (the "Clariant masterbatch acquisition") and Clariant Chemicals (India) Limited's masterbatch business (collectively, the "acquisitions"). The notes will be subject to a "special mandatory redemption" in the event that (i) the Clariant masterbatch acquisition is not consummated on or prior to the purchase agreement is terminated, other than in connection with the consummation of the Clariant masterbatch acquisition.

Investor Day CLARIANT MASTERBATCH ACQUISITION DRIVES NEXT LEVEL SPECIALTY TRANSFORMATION December 2019 ACCELERATING GROWTH WITH SUSTAINABLE SOLUTIONS FORWARD-LOOKING STATEMENTS PolyOne Corporation 2 In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: • The time required to consummate the proposed acquisitions described in this presentation; • The satisfaction or waiver of conditions in the purchase agreements for the proposed acquisitions; • Any material adverse changes in the business of Clariant’s Color and Additive Masterbatch business; • The ability to obtain required regulatory or other third-party approvals and consents and otherwise consummate the proposed acquisitions; • Our ability to achieve the strategic and other objectives relating to the proposed acquisitions, including any expected synergies; • Our ability to successfully integrate Clariant’s Color and Additive Masterbatch business and achieve the expected results of the acquisitions, including, without limitation, the acquisitions being accretive; • Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; • The effect on foreign operations of currency fluctuations, tariffs and other political, economic and regulatory risks; • Changes in polymer consumption growth rates and laws and regulations regarding plastics in jurisdictions where we conduct business; • Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; • Fluctuations in raw material prices, quality and supply, and in energy prices and supply; • Production outages or material costs associated with scheduled or unscheduled maintenance programs; • Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; • An inability to raise or sustain prices for products or services; • An ability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to acquisition and integration, working capital reductions, costs reductions and employee productivity goals; • Information systems failures and cyberattacks; and • Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation. Sources Cash from Balance Sheet $465 New Senior Unsecured Notes 650 New Equity 450 Total Sources $1,565 Uses Clariant Masterbatch $1,500 Clariant India Masterbatch 60 Less: Lease Adjustment (113) Net Purchase Price $1,447 Net Cash Acquired 57 Fees, Expenses & OID 61 Total Uses $1,565 ($ Millions) Cash and Cash Equivalents $370 $450M Senior Secured ABL Revolver - Senior Secured Term Loan B due 2026 624 Other Debt 25 Total Senior Secured Debt $649 5.25% Senior Unsecured Notes due 2023 $600 New Senior Unsecured Notes 650 Total Senior Debt $1,899 Net Debt $1,529 New Equity $450 Pro Forma Capitalization (1) PF 12/31/2019 $450 $600 $624 $743 2019 2020 2021 2022 2023 2024 2025 2026 A T T R A C T I V E F I N A N C I N G S T R U C T U R E Attractive Debt Maturity Profile Existing Revolver Existing Senior Notes Existing Term Loan B New Debt Summary Terms on New Debt  $465 million of cash from the balance sheet expected to fund a portion of the purchase price  Bridge financing for remainder fully committed from Citi, Morgan Stanley and Wells Fargo  Permanent financing expected to include a combination of long-term debt and new equity  The timing of the permanent financing is subject to a number of factors, including, but not limited to, market conditions  PolyOne is committed to preserving a strong balance sheet – Target net leverage at close below 3.5x, excluding synergies  Pro forma capital structure positions PolyOne with flexibility to pursue continued growth strategy  New financing expected to have same or better covenant package than existing capital structure  Capital structure would be “covenant lite” Capital Policy  Transaction in line with PolyOne’s disciplined capital allocation policy  Existing PolyOne dividend policy to be maintained  Focus on deleveraging in the near term 2028+ PolyOne Corporation 26 PolyOne Corporation 27 T H E N E W P O L Y O N E : A S P E C I A L T Y G R O W T H C O M P A N Y  Landmark portfolio transformation: > 85% of Adjusted EBITDA from specialty solutions  World-class innovation, technology and service are differentiators  Sustainability initiatives and alignment with megatrends drive above market growth in key end markets and applications:  Capital management is a strength - proven track record of expanding ROIC while increasing invested capital Transaction expected to add $0.85 to pro forma adjusted EPS PolyOne Corporation 28 PolyOne Corporation 29

Homepage // News Center // Avient’s Malmö, Sweden Site Earns ISCC PLUS Certification for Mevopur™ Healthcare Bio-based Polymer Solutions Mevopur™ Healthcare Bio-based Polymer Solutions manufactured in Malmö, Sweden, are now ISCC PLUS certified. Like other Mevopur products, the bio-based polymer solutions are formulated with raw materials pre-tested to ISO, USP, EP, and ICH Q3D protocols, supporting their compliance with safety and regulatory requirements for use in healthcare.  

Substance Safety Summary SUBSTANCE: Silicon Dioxide GENERAL STATEMENT This summary is intended to provide a general overview of the chemical substance listed above. Additional information is available through the relevant Safety Data Sheet (SDS). The usual precautions, occupational exposure limits for inert dusts, industrial hygiene and occupational safety measure for handling chemicals should be observed.

Mevopur™ Healthcare Functional Additives Antistatic Additive APPLICATION BULLETIN Plastics often undergo charge build-up, which can lead to handling problems and electrical discharges. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

PHYSICAL/CHEMICAL PROPERTIES CATEGORY DETAIL EC Number 236-675-5 CAS Number 13463-67-7 Name Subclass 1 Titanium Dioxide (TiO2) Structural Formula O======Ti====== O PROPERTY DETAIL Physical State Solid Form Crystalline Color White Odor Odorless Melting Point 1560–1843°C Boiling Point 3,000°C Bulk Density 3.9 g/mL at 25°C Water Solubility Immiscible HEALTH EFFECTS HUMAN HEALTH SAFETY ASSESSMENT Consumer Based on available data, TiO2 is not a hazardous substance. Worker Workers should follow the recommended safety measures contained within the Safety Data Sheet (SDS) and on any product packaging. EXPOSURE HUMAN HEALTH SAFETY ASSESSMENT Human Health The substance is used in industrial settings only.

This is where the MEVOPUR product line, and local availability from Taiwan, become extremely important.”  We aim to limit non-compliance risk and support safety in use by using only raw materials that have been specially tested in accordance with medical standards. The certification of this fourth MEVOPUR site provides further proof of our commitment to the healthcare industry and to helping our customers achieve their product safety requirements.”

Save and share the full guide as a PDF for future reference. Download PDF